IN8bio Schedules May 21 R&D Day, to Reveal Glioblastoma and TCE Platform Data
INAB•IN8bio will host an R&D Day on May 21, 2026, featuring updates on its γδ T cell engager (INB-600) platform and INB-200 autologous γδ T cell therapy in newly diagnosed glioblastoma. The company will share Phase I glioblastoma survival benefits data and translational findings at ASGCT, ISCT and ASCO conferences.
1. R&D Day Presentation Details
On May 21, 2026, IN8bio will host an in-person and virtual R&D Day in New York from 9:00 AM to 11:30 AM EDT, showcasing its γδ T cell engager (INB-600) platform for autoimmune diseases and clinical γδ T cell programs in glioblastoma, featuring insights from Dr. David Reardon of Dana-Farber.
2. Conference Poster and Oral Presentations
IN8bio will present four abstracts across three conferences: two posters at ISCT in Dublin on May 7, an oral presentation at ASGCT in Boston on May 14, and a Phase I GBM poster at ASCO in Chicago on June 1, covering γδ T cell therapy interactions, infrastructure efficiencies and GBM study outcomes.
3. Clinical Data Highlights
Key presentations include translational advances demonstrating observed survival benefits in DeltEx DRI treated glioblastoma patients and detailed characterization of gene-modified autologous γδ T cells (INB-200) in newly diagnosed GBM multiforme.
4. Pipeline Overview
IN8bio’s pipeline is anchored by INB-600, a novel γδ T cell engager platform for oncology and autoimmune indications, alongside INB-100 allogeneic γδ T cells for high-risk leukemias and INB-200/400 autologous γδ T cell candidates targeting newly diagnosed glioblastoma.
